Abstract: Battery recharging devices include a power port, a user interface module for receiving a user input, a charge profile generator responsive to the user input for producing a charge profile, and a switch for enabling a current to flow to the battery based upon the charge profile. The charge profile is associated with a set of charges that are adapted to be applied to the battery during a user-defined time period. The set of charges comprises a first charge adapted to be applied to the battery during the user-defined time period during which the battery does not recharge. Methods of recharging batteries are also disclosed.

Abstract: Battery recharging devices include a power port, a user interface module for receiving a user input, a charge profile generator responsive to the user input for producing a charge profile, and a switch for enabling a current to flow to the battery based upon the charge profile. The charge profile is associated with a set of charges that are adapted to be applied to the battery during a user-defined time period. The set of charges comprises a first charge adapted to be applied to the battery during the user-defined time period during which the battery does not recharge. Methods of recharging batteries are also disclosed.

Abstract: Methods of inhibiting the growth of tumors comprising administering chimeric fusion molecules comprising endostatin mutants and all or a portion of anti-Her2 or anti-EGFR antibodies.

Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.

Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.

Abstract: Compositions for treatment of cancer comprising chimeric fusion molecules that bind to an antigen on a pathogenic cell and to an immune cell. The molecules redirect the immune cells to a pathogenic cell. The purified fusion proteins demonstrated ability to bind antigen on the surface of tumor cells and cell surface receptors on immune cells such as NK cells. The chimeric fusion proteins showed increased cytotoxic activity directed against tumor targets.

Abstract: The invention features new helper virus-free methods for making herpesvirus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). Described herein are methods of making helper virus-free HSV amplicon particles; cells that contain those particles (e.g., packaging cell lines or patients' cells, infected in vivo or ex vivo); particles produced according to those methods; and methods of treating a patient with an hf-HSV particle made according to those methods.

Abstract: Chimeric molecules comprising endostatin and all or a portion of an Ig (Ig) molecule are used to treat tumors. A chimeric molecule, including endostatin fused to an Ig domain of an anti-HER2/neu antibody exhibited longer serum half-life and stability than native endostatin. 125I-labeled anti-HER2/neu IgG3-endostatin chimeric molecule and anti-HER2/neu IgG3 preferentially localized to CT26-HER2 tumors. Clearance of anti-HER2/neu IgG3-endostatin was 6 fold faster than that of anti-HER2/neu IgG3 (CLss=0.374 and 0.062 ml/min/kg, respectively), however, the specific tumor radiolocalization indices of anti-HER2/neu IgG3-endostatin were greater than those of anti-HER2/neu IgG3. Anti-HER2/neu IgG3-endostatin inhibited tumor growth more effectively than endostatin alone, anti-HER2/neu IgG3 antibody, or the combination of antibody and endostatin.